The effect of polyethylene glycol spacer chain length on the tumor-targeting potential of folate-modified PPI dendrimers
Source abstract
Abstract
The objective of the present investigation was to assess the tumor-targeting potential of ligand-spacer-engineered poly (propylene imine) (PPI) dendrimers as nanoscale drug delivery units for site-specific delivery of a model anticancer agent, docetaxel (DTX). PPI dendrimers were engineered by direct and indirect conjugation of folic acid (FA) via different types of polyethylene glycols (PEGs) [Mw (molecular weight): 1,000, 4,000, 6,000, 7,500] as spacers. The synthesized nanoconjugates (PPIFA, PPIP1FA, PPIP4FA, PPIP6FA, and PPIP7.5FA) were characterized by Fourier transform infrared spectroscopy, nuclear magnetic resonance (1H-NMR) and transmission electron microscopic (TEM) studies. Nanoconjugates were evaluated for entrapment, in vitro drug release (under various pH conditions) and hemolytic studies. Cell uptake and cytotoxicity studies were performed on human malignant cell lines (MCF-7) using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide [MTT] assay. This debut study explored the effect of PEG spacer length on the targeting potential of folate-conjugated 5.0 G PPI dendrimer. DTX entrapment and in vitro drug release from nanoconjugates augmented, and hemolytic toxicity of nanoconjugates slashed with the molecular weight of PEGs. Further, nanoconjugates with PEG 4000 displayed highest tumor-targeting potential as compared to other spacer conjugated nanoconjugates due to optimized steric hindrance and receptor mediated endocytosis among other PEGs. This work is expected to shed new light on the role of spacer chain length in targeting potential of folate-anchored dendrimer.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Dendrimers and Hyperbranched Polymers · RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (62)
Show source-provided references
1. Agarwal A, Gupta U, Asthana A, Jain NK (2009) Dextran conjugated dendrtitic nanoconstructs as potential vectors for anti-cancer agent. Biomaterials 30:3588–359610.1016/j.biomaterials.2009.03.016 ↗
2. Agashe HB, Babbar AK, Jain S, Sharma RK, Mishra AK, Asthana A, Garg M, Dutta T, Jain NK (2007) Investigations on biodistribution of technetium-99 m-labeled carbohydrate-coated poly(propylene imine) dendrimers. Nanomedicine 3:120–12710.1016/j.nano.2007.02.002 ↗
3. Asthana A, Chauhan AS, Diwan PV, Jain NK (2005) Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient. AAPS PharmSciTech 6:E536–E54210.1208/pt060367 ↗
4. Bhadra D, Bhadra S, Jain S, Jain NK (2003) A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 25:7111–7124
5. Bhadra D, Bhadra S, Jain NK (2005) PEGylated lysine based copolymeric dendritic micelles for solubilization and delivery of artemether. J Pharm Sci 8:467–482
6. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–165910.1016/j.addr.2004.02.014 ↗
7. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54:631–65110.1016/S0169-409X(02)00044-3 ↗
8. De Brabander-van Den Berg EMM, Meijer EW (1993) PPI dendrimers: large-scale synthesis by hetereogeneously catalyzed hydrogenations. Angew Chem Int Ed Engl 32:1308–131110.1002/anie.199313081 ↗
9. Dutta T, Jain NK (2007) Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim Biophys Acta 1770:681–68610.1016/j.bbagen.2006.12.007 ↗
10. Dutta T, Agashe HB, Garg M, Balakrishnan P, Kabra M, Jain NK (2007) Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J Drug Target 15:89–9810.1080/10611860600965914 ↗
11. Dutta T, Garg M, Jain NK (2008) Poly(propyleneimine) dendrimer and dendrosome mediated genetic immunization against hepatitis B. Vaccine 26:3389–339410.1016/j.vaccine.2008.04.058 ↗
12. Gajbhiye V, Jain NK (2011) The treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials 32:6213–622510.1016/j.biomaterials.2011.04.057 ↗
13. Gajbhiye V, Kumar PV, Tekade RK, Jain NK (2007) Pharmaceutical and biomedical potential of PEGylated dendrimers. Curr Pharm Des 13:415–42910.2174/138161207780162999 ↗
14. Goddard JM, Erickson D (2009) Bioconjugation techniques for microfluidic biosensors. Anal Bioanal Chem 394:469–47910.1007/s00216-009-2731-y ↗
15. Grabarek Z, Gergely J (1990) Zero-length crosslinking procedure with the use of active esters. Anal Biochem 185:131–13510.1016/0003-2697(90)90267-D ↗
16. Guillaudeu SJ, Fox ME, Haidar YM, Dy EE, Szoka FC, Fréchet JM (2008) PEGylated dendrimers with core functionality for biological applications. Bioconjug Chem 19:461–46910.1021/bc700264g ↗
17. Gupta U, Agashe HB, Jain NK (2007) Polypropylene imine dendrimer mediated solubility enhancement: effect of pH and functional groups of hydrophobes. J Pharm Sci 10:358–367
18. Ho J, Al-Deen FM, Al-Abboodi A, Selomulya C, Xiang SD, Plebanski M, Forde GM (2011) N,N′-Carbonyldiimidazole-mediated functionalization of superparamagnetic nanoparticles as vaccine carrier. Colloids Surf B Biointerfaces 83:83–9010.1016/j.colsurfb.2010.11.001 ↗
19. Hwa KS, Hoon JJ, Joe CO, Gwan PT (2005) Folate receptor mediated intracellular protein delivery using PLL-PEG-FOL conjugate. J Control Rel 103:625–63410.1016/j.jconrel.2005.01.006 ↗
20. Jabr-Milane LS, Van Vlerken L, Yadav S, Amiji MM (2008) Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 34:592–60210.1016/j.ctrv.2008.04.003 ↗
21. Jain NK, Asthana A (2007) Dendritic systems in drug delivery applications. Expert Opin Drug Deliv 4:495–51210.1517/17425247.4.5.495 ↗
22. Kaminskas LM, Kelly BD, McLeod VM, Sberna G, Owen DJ, Boyd BJ, Porter CJ (2011) Characterization and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. J Control Release 152:241–24810.1016/j.jconrel.2011.02.005 ↗
23. Kannan S, Kolhe P, Raykova V, Glibatec M, Kannan RM, Lieh-Lai M, Bassett D (2004) Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells. J Biomatter Sci Polym Ed 15:311–33010.1163/156856204322977201 ↗
24. Kesharwani P, Tekade RK, Gajbhiye V, Jain K, Jain NK (2011) Cancer targeting potential of some ligand anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine 7:295–30410.1016/j.nano.2010.10.010 ↗
25. Kim Y, Klutz AM, Jacobson KA (2008) Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity. Bioconjug Chem 19:1660–167210.1021/bc700483s ↗
26. Kingsley JD, Dou H, Morehead J, Rabinow B, Gendelman HE, Destache CJ (2006) Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol 1(340):350
27. Kobayashi H, Kawamoto S, Saga T, Sato N, Hiraga A, Ishimori T, Konishi J, To-Gashi K, Brechbiel MW (2001) Positive effects of polyethylene glycol conjugation to generation-4 polyamidoamine dendrimers as macromolecular MR contrast agents. Magn Reson Med 46:781–78810.1002/mrm.1257 ↗
28. Kojima C, Regino C, Umeda Y, Kobayashi H, Kono K (2010) Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. Int J Pharm 383:293–30610.1016/j.ijpharm.2009.09.015 ↗
29. Kolhe P, Khandare J, Pillai O, Kannan S, Lai ML, Kannan RM (2006) Preparation, cellular transport, and activity of polyamidoamine based dendritic nanodevices with a high drug payload. Biomaterials 27:660–66910.1016/j.biomaterials.2005.06.007 ↗
30. Konda SD, Wang S, Brechbiel M, Wiener EC (2002) Biodistribution of a 153 Gd-folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts. Invest Radiol 37:199–20410.1097/00004424-200204000-00005 ↗
31. Kumar PV, Asthana A, Dutta T, Jain NK (2006) Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target 14:546–55610.1080/10611860600825159 ↗
32. Kumar PV, Agashe H, Dutta T, Jain NK (2007) PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug. Curr Drug Deliv 1:11–1910.2174/156720107779314794 ↗
33. Kwon GS, Okano T (1996) Polymeric micelles as new drug carriers. Adv Drug Deliv Rev 16:107–11610.1016/S0169-409X(96)00401-2 ↗
34. Lee RJ, Low PS (1995) Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233:134–14410.1016/0005-2736(94)00235-H ↗
35. Lim J, Guo Y, Rostollan CL, Standfield J, Hsieh JT, Sun X, Simanek EE (2008) The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers. Mol Pharm 5:540–54710.1021/mp8000292 ↗
36. Liu Y, Li K, Pan J, Liu B, Feng SS (2010) Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials 31:330–33810.1016/j.biomaterials.2009.09.036 ↗
37. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–6310.1016/0022-1759(83)90303-4 ↗
38. Nie S, Xing Y, Kim GJ, Simons JW (2007) Nanotechnology applications in cancer. Annu Rev Biomed Eng 9:257–28810.1146/annurev.bioeng.9.060906.152025 ↗
39. Okuda T, Kawakami S, Akimoto N, Niidome T, Yamashita F, Hashida M (2006) PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. J Control Release 116:330–33610.1016/j.jconrel.2006.09.012 ↗
40. Patri AK, Majoros I, Baker JR (2002) Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol 6:466–47110.1016/S1367-5931(02)00347-2 ↗
41. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, Patri AK, Thomas T, Mule J, Baker JR (2002) Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19:1310–131610.1023/A:1020398624602 ↗
42. Sabharanjak S, Mayor S (2004) Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 56:1099–110910.1016/j.addr.2004.01.010 ↗
43. Sideratou Z, Kontoyianni C, Drossopoulou GI, Paleos CM (2010) Synthesis of a folate functionalized PEGylated poly(propylene imine) dendrimer as prospective targeted drug delivery system. Bioorg Med Chem Lett 20:6513–652710.1016/j.bmcl.2010.09.058 ↗
44. Singh P, Gupta U, Asthana A, Jain NK (2008) Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem 19:2239–225210.1021/bc800125u ↗
45. Singhai AK, Jain S, Jain NK (1997) Evaluation of an aqueous injection of Ketoprofen. Pharmazie 52:149–151
46. Sinha R, Kim GJ, Nie S, Shin DM (2006) Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 5:1909–191710.1158/1535-7163.MCT-06-0141 ↗
47. Stewart BW, Kleihues P (2003) World Cancer Report WHO. International Agency for Research on Cancer, IARC Press, Lyon, France10.1016/S0140-6736(03)12634-7 ↗
48. Sudimack J, Lee RJ (2000) Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41:147–16210.1016/S0169-409X(99)00062-9 ↗
49. Tekade RK, Dutta T, Tyagi A, Bharti AC, Das BC, Jain NK (2008) Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. J Drug Target 16:758–77210.1080/10611860802473154 ↗
50. Tekade RK, Dutta T, Gajbhiye V, Jain NK (2009a) Exploring dendrimers towards dual–drug delivery: pH responsive simultaneous kinetics. J Microencapsul 26:287–29610.1080/02652040802312572 ↗
51. Tekade RK, Kumar PV, Jain NK (2009b) Dendrimers in oncology: an expanding horizon. Chem Rev 109:49–8710.1021/cr068212n ↗
52. Thomas TP, Majoros IJ, Kotlyar A, Kukowska-Latallo JF, Bielinska A, Myc A, Baker JR (2005) Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem 48:3729–373510.1021/jm040187v ↗
53. Tomalia DA (1996) Starburst dendrimers-nanoscopic supermolecules according dendritic rules and principles. Macromol Symp 101:243–25510.1002/masy.19961010128 ↗
54. Tomalia DA, Naylor AM, Goddard WA (1990) Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Ed Engl 29:138–17510.1002/anie.199001381 ↗
55. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H (2003) Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 94:15–2110.1111/j.1349-7006.2003.tb01345.x ↗
56. Wolinsky JB, Grinstaff MW (2008) Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev 60:1037–105510.1016/j.addr.2008.02.012 ↗
57. Yang H, Stephanie T, Lopina ST (2003) Penicillin V-conjugated PEG-PAMAM star polymers. J Biomater Sci Polym 14:1043–105610.1163/156856203769231556 ↗
58. Zange R, Li Y, Kissel T (1998) Biocompatibility testing of ABA copolymers consisting of poly (l-lactic-co-glycolic acid) A blocks attached to a central poly (ethylene oxide) B block under in vitro conditions using different L929 mouse fibroblast cell culture models. J Control Release 56:249–25810.1016/S0168-3659(98)00093-5 ↗
59. Zhai G, Wu J, Xiang G, Mao W, Yu B, Li H, Piao L, Lee LJ, Lee RJ (2009) Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J Nanosci Nanotechnol 9:2155–216110.1166/jnn.2009.450 ↗
60. Zhao XF, Dong L, Zheng W (2011) PEGylated thermo sensitive poly(amidoamine) dendritic drug delivery systems. Int J Pharm 100:123–131
61. Zhou QS, Jiang XH, Yu JR, Li KJ (2006) Synthesis and characterization of PEG-scutellarin conjugates, a potential PEG ester prodrug for the oral delivery of scutellarin. Chin Chem Lett 1:85–88
62. Zhu S, Hong M, Tang G, Qian L, Lin J, Jiang Y, Pei Y (2010) Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 31:1360–137110.1016/j.biomaterials.2009.10.044 ↗